SynthesisJournal of robotic surgery2025
Perioperative functional and oncologic outcomes of percutaneous thermal ablation (PTA) versus robot-assisted partial nephrectomy (RAPN) for cT1 renal tumors: a systematic review and meta-analysis.
Synthesis in Journal of robotic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is ongoing debate on the relative safety and effectiveness of robot-assisted partial nephrectomy (RAPN) and percutaneous thermal ablation (PTA) in the treatment of cT1 renal cancers. The purpose of this study was to compare the oncological, functional, and perioperative results of these two approaches. Web of Science, PubMed, Cochrane Library, and EMBASE were used in a systematic review to find English-language research that was published before to August 2025. Review Manager 5.4 was used to do a meta-analysis, combining five trials with 773 patients (398 treated with PTA and 375 with RAPN). Weighted mean differences (WMD) were utilized for continuous variables, while odds ratios (OR) were used for dichotomous variables. PROSPERO registered the study (ID: CRD420251125197). PTA was associated to a reduced postoperative glomerular filtration rate (WMD: -14.14; 95% CI: -23.77 to -4.15; P = 0.004), a higher local recurrence rate (OR: 4.14; 95% CI: 1.63-10.53; P = 0.003), and a significantly shorter operative time (WMD: -86.41 min; 95% CI: -143.58 to -29.24; P = 0.003) when compared to RAPN. The duration of hospital stays, the rate of postoperative glomerular filtration rate drop, serious complications (Clavien-Dindo grade ≥ III), the risk of metastases, and 5-year overall survival (OS) did not, however, differ significantly between the two groups. According to our research, PTA and RAPN are both safe and efficient ways to treat cT1 renal tumors while maintaining a similar level of renal function. For individuals with pre-existing renal impairment or poor overall health, PTA could be a better option.
Indexed as
Identifiers
41217701What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.